Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes

Diabetic Medicine

Volumn 27, Issue 5, 2010, Pages 563-569

  Chacra, A R ^a   Kipnes, M ^b   Ilag, L L ^c   Sarwat, S ^c   Giaconia, J ^c   Chan, J ^c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b DGD Research   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Basal bolus; Insulin analogue; Insulin detemir; Lispro; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMALOG BASAL; HUMALOG MIX25; HUMALOG MIX50; HUMALOG N; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN LISPRO; INSULIN LISPRO PROTAMINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFLUENZA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SUSPENSION; TREATMENT DURATION; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED;

EID: 77951261032     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.02986.x     Document Type: Article

References (30)

1. Rossetti P, Porcellati F, Bolli GB, Fanelli CG. Prevention of hypoglycemia while achieving good glycemic control in Type 1 diabetes: the role of insulin analogs. Diabetes Care 2008 31 : S113 S120.
2. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004 47 : 622 629. (Pubitemid 38658363)
3. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004 27 : 1081 1087. (Pubitemid 38579770)
4. Novo Nordisk. Levemir package insert. Available at http://www. novonordiskcare.com/downloads/levemir-prescribing-information.pdf Last accessed 23 September 2009.
5. Le Floch J-P, Levy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabetes Care 2009 32 : 32 37.
6. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008 25 : 442 449. (Pubitemid 351490120)
7. Korsatko S, Glettler K, Olsen KJ, Wutte A, Bock G, Koehler G et al. Action of insulin and its analogues. Diabetologia 2009 52 : S200.
8. Hompesch M, Ocheltree SM, Wondmagegnehu ET, Morrow LA, Kollmeier AP, Campaigne BN et al. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009 25 : 2679 2687.
9. Mecklenburg RS. Insulin-pump therapy. In : Lebovitz H, ed. Therapy for Diabetes Mellitus and Related Disorders, 3rd edn.
10. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003 26 : 590 596. (Pubitemid 36929312)
11. Hirsch IB, Yuan H, Campaigne BN, Tan MH. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract 2009 15 : 343 348.
12. Zhou J, Jia W, Bao Y, Ma X, Lu W, Li H et al. Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med Sci Monit 2008 14 : CR552 CR558.
13. American Diabetes Association. Clinical practice recommendations 2005. Diabetes Care 2005 28 : S1 S79.
14. ADA Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on hypoglycemia. Diabetes Care 2005 28 : 1245 1249.
15. The DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991 90 : 450 459.
16. Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract 2001 55 : 177 182. (Pubitemid 32390155)
17. Westfall PH, Krishen A. Optimally weighted, fixed sequence and gatekeeper multiple testing procedures. J Stat Plann Inferface 2001 99 : 25 40. (Pubitemid 33619467)
18. American Diabetes Association. Clinical practice recommendations. Available at http://care.diabetesjournals.org/content/32/Supplement1 Last accessed 23 September 2009.
19. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. J Am Med Assoc 2003 289 : 2254 2264. (Pubitemid 37430194)
20. Saunders SA, Wallymahmed M, MacFarlane IA. Glycaemic control in a type 1 diabetes clinic for younger adults. Q J Med 2004 97 : 575 580. (Pubitemid 39214324)
21. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005 7 : 73 82.
22. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005 22 : 850 857.
23. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004 26 : 724 736.
24. Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA et al. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 2007 24 : 635 642.
25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
26. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 2653.
27. Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm diabetes intervention study (SDIS) at 10-year follow up. Diabetologia 1996 39 : 1483 1488.
28. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 49 : 999 1005.
29. Swinnen SG, Devries JH. Higher dose requirements with insulin detemir in type 2 diabetes - three cases and a review of the literature. Diabetes Res Clin Pract 2009 84 : e24 e26.
30. Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007 30 : 2447 2452.